Does the nitric oxide donor JS-K enhance sunitinib-mediated effects on brain tumor initiating cells in vitro?

M. Schrödl, N. Osterberg, P. Hau, S. Möckel, A.V. Vollmann-Zwerenz & A. Weyerbrock
Objective: The dismal prognosis of glioblastoma multiforme (GBM) emphasizes the need for personalized multimodal treatment based on cellular, genetic and epigenetic characteristics. Experimental strategies include small-molecule, multitargeting tyrosine kinase inhibitors such as sunitinib and the exploration[for full text, please go to the a.m. URL]